The association of discharge lipid-lowering therapy (LLT) and outcomes
| Total | Events (n%) | HR (95% CI) unadjusted | P value | HR (95% CI) adjusted | P value | |
| 3 months | ||||||
| Stroke recurrence | ||||||
| Discharge LLT | 13 248 | 269 (2.0) | 0.68 (0.48 to 0.96) | 0.03 | 0.69 (0.48 to 0.99) | 0.04 |
| Non-discharge LLT | 1181 | 35 (3.0) | Reference | Reference | ||
| Ischaemic stroke | ||||||
| Discharge LLT | 13 263 | 245 (1.9) | 0.68 (0.47 to 0.98) | 0.04 | 0.65 (0.45 to 0.94) | 0.02 |
| Non-discharge LLT | 1188 | 32 (2.7) | Reference | Reference | ||
| Haemorrhagic stroke | ||||||
| Discharge LLT | 13 740 | 31 (0.2) | 0.71 (0.25 to 2.01) | 0.52 | 1.19 (0.36 to 3.98) | 0.78 |
| Non-discharge LLT | 1266 | 4 (0.3) | Reference | Reference | ||
| MACE | ||||||
| Discharge LLT | 13 248 | 299 (2.3) | 0.71 (0.51 to 1.003) | 0.052 | 0.74 (0.52 to 1.04) | 0.08 |
| Non-discharge LLT | 1181 | 37 (3.1) | Reference | Reference | ||
| 12 months | ||||||
| Stroke recurrence | ||||||
| Discharge LLT | 13 248 | 758 (5.7) | 0.88 (0.7 to 1.12) | 0.30 | 0.89 (0.7 to 1.14) | 0.36 |
| Non-discharge LLT | 1181 | 75 (6.4) | Reference | Reference | ||
| Ischaemic stroke | ||||||
| Discharge LLT | 13 263 | 683 (5.2) | 0.87 (0.68 to 1.11) | 0.26 | 0.86 (0.67 to 1.10) | 0.23 |
| Non-discharge LLT | 1188 | 69 (5.8) | Reference | Reference | ||
| Haemorrhagic stroke | ||||||
| Discharge LLT | 13 740 | 86 (0.6) | 0.97 (0.47 to 2.00) | 0.94 | 1.23 (0.56 to 2.69) | 0.60 |
| Non-discharge LLT | 1266 | 8 (0.6) | Reference | Reference | ||
| MACE | ||||||
| Discharge LLT | 13 248 | 838 (6.3) | 0.94 (0.75 to 1.19) | 0.60 | 0.96 (0.76 to 1.21) | 0.72 |
| Non-discharge LLT | 1181 | 78 (6.6) | Reference | Reference |
Patients who reached the endpoint (stroke recurrence or MACE, death and loss to follow-up) during hospitalisation were excluded.
MACE, major adverse cardiovascular events.